Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by mercedesmanon Mar 04, 2021 11:19am
121 Views
Post# 32715045

RE:RE:RE:Cresendo Communication served V.IPA well for their US gambit

RE:RE:RE:Cresendo Communication served V.IPA well for their US gambit
Accountprince wrote: Crescendo was appointed a while back - not sure why they are now announcing again.  The share price went to lofty heights in February when it was announced Dr Kellum was coming on board.  With him joining this week and today's re-release of the Crescendo appointment we touched $0.60 per share.  A stunning 20% drop in price so far.

It's not business fundamentals as nothing has been announced.  So either the market views Dr Kellum joining along with Crescendo appointment negatively (why?) or there is manipulation of the share price as has been suggested for some time now (again why?).  Logic dictates one or the other.


Hey AP

Not sure that Crescendo was ever previously announced.  It was sussed out by some observant posters here (teh US IR firm's name mysteriously and suddenly appeared at the bottom of another unrelated release, hence the "Where's Walden" quips).   Not sure why the delay.

As to your either/or proposition.  The first is unlikely.  The second may have some validity.
But I prefer a third possibility.
And that is that the market for undervalued, under-promoted Cdn stocks is highly inefficient.  Daily movements cannot be easily explained by news releases.  The only thing that make markets more efficient, and that can result in better or true value discovery is (1) more effective marketing and (2) more volume (preferably brought about by US dissemination and therefor higher demand).

Of course, low volume, off the radar stocks are subject to more manipulation at the hands of various (nefarious?) groups...whose interests vary over time.
Marketing, volume and being on the best exchange (ideally one that best matches the ultimate target market of the company) is the best solution to that problem.

IMHO

MM

<< Previous
Bullboard Posts
Next >>